Management of Long-COVID Postural Orthostatic Tachycardia Syndrome With Enhanced External Counterpulsation.

covid long haul syndrome eecp long covid pasc postural orthostatic tachycardia syndrome

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
Sep 2021
Historique:
accepted: 29 09 2021
entrez: 3 11 2021
pubmed: 4 11 2021
medline: 4 11 2021
Statut: epublish

Résumé

A growing number of patients diagnosed with COVID-19 disease have been reported to have postural orthostatic tachycardia syndrome (POTS) after the acute phase. A 57-year-old female was diagnosed with COVID-19 in December 2020. As a result of her acute illness, she was hospitalized for COVID pneumonia and respiratory failure, followed by stays at an acute care facility and home rehabilitation center. After the acute phase, the patient was diagnosed with long-COVID-19-associated POTS with symptoms such as fatigue, "brain fog," and dyspnea. The patient was referred to an enhanced external counterpulsation (EECP) treatment center and underwent 15, one-hour sessions over three weeks. Upon completion of therapy, the patient reported improvements with "brain fog" and the ability to perform activities of daily living. Her Patient-Reported Outcome Measurement Information System (PROMIS) Fatigue score was reduced by three points, six-minute walk distance increased by 85 feet, and Duke Activity Status Index (DASI) improved by over 15 points. EECP therapy was chosen due to the overlap in underlying pathology driving POTS and the mechanisms of action of EECP. This report is the first case of using EECP for the successful management of COVID-19-associated POTS and warrants further trials.

Identifiants

pubmed: 34729276
doi: 10.7759/cureus.18398
pmc: PMC8555928
doi:

Types de publication

Case Reports

Langues

eng

Pagination

e18398

Informations de copyright

Copyright © 2021, Varanasi et al.

Déclaration de conflit d'intérêts

The authors have declared financial relationships, which are detailed in the next section.

Références

Circulation. 2010 Oct 19;122(16):1612-20
pubmed: 20921442
Hypertension. 2021 Mar 3;77(3):1001-1009
pubmed: 33486983
Ann Clin Transl Neurol. 2018 Feb 28;5(4):486-492
pubmed: 29687025
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
J Am Coll Cardiol. 2019 Mar 19;73(10):1207-1228
pubmed: 30871704
N Engl J Med. 2021 Aug 12;385(7):577-579
pubmed: 34192429
Immunol Res. 2021 Apr;69(2):205-211
pubmed: 33786700
Scand Cardiovasc J. 2017 Oct;51(5):243-247
pubmed: 28738696
Cureus. 2021 Apr 7;13(4):e14358
pubmed: 33987042
JACC Case Rep. 2021 Apr;3(4):573-580
pubmed: 33723532
Sci Rep. 2021 Aug 9;11(1):16144
pubmed: 34373540

Auteurs

Swathi Varanasi (S)

Medical Affairs, Flow Therapy, Fort Worth, USA.

Mohankrishnan Sathyamoorthy (M)

Internal Medicine, University of North Texas Health Science Center, Fort Worth, USA.

Sanjayanth Chamakura (S)

Cardiology, Medical City North Hills, North Richland Hills, USA.

Sachin A Shah (SA)

Pharmacy, University of the Pacific, Stockton, USA.

Classifications MeSH